Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares

• Published in: Rheumatic & musculoskeletal diseases open 2022-09, Vol.8 (2), p.e002460
• Main Authors: Carubbi, Francesco, Alunno, Alessia, Santilli, Jessica, Natali, Laura, Mancini, Bernardina, Di Gregorio, Nicoletta, Del Pinto, Rita, Viscido, Angelo, Grassi, Davide, Ferri, Claudio
• Format: Article
• Language: English
• Subjects: Arthritis; Autoimmunity; COVID-19; Drug dosages; Dyspnea; epidemiology; Fainting; Hospitals; Inflammatory diseases; Internal medicine; Nephrology; Pain; Rheumatology; Severe acute respiratory syndrome coronavirus 2; Thrombosis; vaccination; Vaccines
• ISSN: 2056-5933; 2056-5933
• DOI: 10.1136/rmdopen-2022-002460

ObjectiveNew-onset immune-mediated inflammatory diseases (IMIDs) and flares of pre-existing IMIDs have been reported following anti- SARS-CoV2 vaccination. Our study aimed at describing a retrospective cohort of patients developing new-onset IMIDs or flares of known IMIDs within 30 days after any anti-SARS-CoV2 vaccine dose.MethodsWe evaluated clinical records of all inpatients and outpatients referring to our institution between February 2021 and February 2022 with any clinical manifestations. We then selected those having received any anti-SARS-CoV2 vaccine dose within the prior 30 days and classified them as having or not a previous IMID according to predefined criteria. We recorded new-onset IMIDs or flares of known IMIDs and investigated any relationship with demographic, clinical and serological variables.Results153 patients that received any anti-SARS-CoV2 vaccine dose within the previous 30 days were included of which 45 (29%) already had a diagnosis of IMID while 108 (71%) had no previously diagnosed IMID. 33 (30%) of the 108 patients, were diagnosed with a new-onset IMID. Pericarditis, polymyalgia rheumatica and vasculitis were the most frequent conditions. Among the 45 patients that already had an IMID, disease flare was the reason for referral in 69% of patients. Patients with an IMID flare had a lower number of comorbidities and tended to be younger compared with those who developed other conditions after anti-SARS-CoV2 vaccination.ConclusionWe provided a retrospective overview of a cohort of patients who developed new-onset IMIDs or flares of known IMIDs within 30 days after any dose of anti-SARS-CoV2 vaccine. While vaccination campaigns proceed, postvaccination surveillance programmes are ongoing and hopefully will soon clarify whether a causal relationship between vaccines and new-onset/flares of IMIDs exists.